Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9706968 | 1.00 | KMT2A (0.45) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL12555211 | 0.95 | KMT2A (0.47) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL17192730 | 0.92 | KMT2A (0.45) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL8410923 | 0.92 | KMT2A (0.45) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL12873284 | 0.91 | LMNA (0.46) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL1623874 | 0.91 | KMT2A (0.44) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL12588064 | 0.89 | KMT2A (0.42) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL3367289 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL16316701 | 0.89 | KMT2A (0.42) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL14416300 | 0.89 | KMT2A (0.42) | KMT2AMEN1MDM2CASP3FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517854-B2 | Melanocortin receptor agonists | NOVO NORDISK A/S (DK) | 2009-04-14 | — | — | US | disclosed |
| US-20070027091-A1 | Novel Melanocortin Receptor Agonists | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| WO-2004097371-A2 | SYSTEM AND METHOD FOR THE DETECTION OF ANALYTES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-0736039-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2000-10-25 | — | — | EP | disclosed |
| US-5998375-A | TREATMENT OV VASOMOTOR DISTURBANCES SUCH AS HOT FLASHES | NOVO NORDISK A/S (DK) | 1999-12-07 | — | — | US | disclosed |
| US-5990084-A | A SERIES OF TRUNCATED ANALOGS OF HGHRH (HUMAN GROWTH HORMONE RELEASING HORMONE); ANALOG ACTIVATES THE GHRH RECEPTOR, BUT HAS IMPROVED METABOLIC STABILITY, DECREASED IMMUNOGENICITY AND LOWER COST OF PRODUCTION | NOVO NORDISK A/S (DK) | 1999-11-23 | — | — | US | disclosed |
| WO-1999003880-A1 | NOCICEPTIN ANALOGUES | NOVO NORDISK A/S (DK) | 1999-01-28 | — | — | WO | disclosed |
| US-5767085-A | PEPTIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 1998-06-16 | — | — | US | disclosed |
| EP-0736039-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017423-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027091-A1 | Novel Melanocortin Receptor Agonists | MC4R, MC3R, MC5R | KMT2A 3423/4885MEN1 875/4885MDM2 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.